Close Menu

COVID-19

Todos said it intends to use part of the proceeds to retire outstanding convertible notes and complete the acquisition of Provista Diagnostics.

Talis, a point-of-care test developer, said that the principal purpose for the offering is to obtain additional capital to support its operations, among other purposes.

The funding will be used to provide free at-home DNA tests to individuals with Long COVID, as well as to advance Sano's data-sharing platform.

The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.

Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.